HC Wainwright Has Pessimistic Outlook of EWTX Q3 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Edgewise Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the company will post earnings per share of ($0.53) for the quarter, down from their previous estimate of ($0.50). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.15) EPS and FY2029 earnings at ($1.24) EPS.

EWTX has been the subject of a number of other reports. Leerink Partners set a $52.00 target price on Edgewise Therapeutics in a research note on Tuesday, June 16th. Royal Bank Of Canada raised their price target on Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 17th. Raymond James Financial reiterated a “strong-buy” rating and set a $66.00 price objective on shares of Edgewise Therapeutics in a report on Monday, June 1st. The Goldman Sachs Group boosted their price objective on Edgewise Therapeutics from $20.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, June 17th. Finally, Wedbush increased their target price on Edgewise Therapeutics from $46.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $48.75.

Edgewise Therapeutics Trading Up 2.4%

Shares of Edgewise Therapeutics stock opened at $44.58 on Monday. The company has a market capitalization of $4.84 billion, a PE ratio of -24.10 and a beta of 0.30. Edgewise Therapeutics has a 12 month low of $12.30 and a 12 month high of $48.40. The stock’s fifty day simple moving average is $39.54 and its 200 day simple moving average is $34.24.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06).

Insider Activity

In other news, insider Alan J. Russell sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total transaction of $7,882,000.00. Following the sale, the insider owned 24,555 shares in the company, valued at $967,712.55. This represents a 89.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 21.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Edgewise Therapeutics

A number of large investors have recently added to or reduced their stakes in EWTX. BlackRock Inc. bought a new position in Edgewise Therapeutics during the second quarter worth about $268,415,000. Morgan Stanley raised its stake in Edgewise Therapeutics by 234.7% in the fourth quarter. Morgan Stanley now owns 2,910,881 shares of the company’s stock valued at $72,234,000 after buying an additional 2,041,203 shares during the period. UBS Group AG raised its stake in Edgewise Therapeutics by 1,755.0% in the fourth quarter. UBS Group AG now owns 2,117,073 shares of the company’s stock valued at $52,535,000 after buying an additional 2,002,945 shares during the period. Janus Henderson Group PLC lifted its position in shares of Edgewise Therapeutics by 29.5% in the first quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock valued at $186,289,000 after buying an additional 1,348,706 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $18,645,000.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.